BridgeBio saw significant revenue growth in Q4 2025, primarily driven by the commercial success of Attruby (acoramidis) following its 2024 FDA approval. The company achieved three positive Phase 3 trial readouts in late 2025 and is preparing for multiple NDA submissions in 1H 2026, transitioning into a multi-product commercial-stage biopharmaceutical company.

BridgeBio reported $110.6M in total revenue for Q2 2025, driven by $71.5M in Attruby product sales and $37.5M in license and services revenue. However, the company posted a net loss of $181.9M due to higher SG&A expenses supporting the commercial launch.

BridgeBio Pharma reported Q4 2024 revenue of $5.9 million, a significant increase from the prior year period, primarily driven by the first commercial sales of Attruby in the U.S. The company faced a net loss of $265.1 million, attributed to increased SG&A expenses related to commercialization efforts. Operating costs surged due to higher marketing and sales expenses, while cash and cash equivalents reached $681 million. The company continues to progress its pipeline with multiple Phase 3 studies advancing towards completion.

BridgeBio Pharma reported its Q3 2024 financial results, highlighting progress in its late-stage pipeline, including the NDA filing for acoramidis and advancements in other clinical trials. The company ended the quarter with $406 million in cash, cash equivalents, and short-term restricted cash.

BridgeBio Pharma reported its Q2 2024 financial results, highlighting progress in preparing for the commercial launch of acoramidis and advancing its Phase 3 clinical programs. The company ended the quarter with $587 million in cash, cash equivalents, marketable securities and short-term restricted cash.

BridgeBio Pharma reported a strong financial position after securing up to $1.5 billion in a Q1 2024 capital campaign and launching BridgeBio Oncology Therapeutics (BBOT) with a $200 million private financing. The company is preparing for the potential launch of acoramidis in the US and anticipates three Phase 3 readouts in 2025. Revenue for the quarter was $211.1 million, primarily due to upfront payments from licensing agreements.

BridgeBio Pharma reported fourth-quarter financial results, with a focus on executing the launch of acoramidis. The company is also focused on fully enrolling three ongoing Phase 3 clinical trials by the end of 2024.

BridgeBio Pharma reported third quarter 2023 financial results, highlighting progress in its late-stage pipeline, including the upcoming launch of its ATTR-CM asset, acoramidis. The company ended the quarter with $522 million in cash, cash equivalents, and short-term restricted cash after raising $316 million via ATM facility and a private placement equity financing.

BridgeBio Pharma reported positive Phase 3 ATTRibute-CM study results for acoramidis and plans to file an NDA with the FDA by the end of 2023. They ended the quarter with $353 million in cash, cash equivalents, marketable securities, and short-term restricted cash, providing runway into 2H 2024.

BridgeBio Pharma reported its Q1 2023 financial results, highlighting the positive results from the Phase 2 trial of infigratinib for achondroplasia and progress in other key programs. The company closed a public offering with gross proceeds of $150 million and ended the quarter with $467 million in cash and cash equivalents.

BridgeBio Pharma reported its Q4 and full year 2022 financial results. The company ended the quarter with $466.2 million in cash, cash equivalents, marketable securities, and restricted cash, providing runway into 2024. Key programs like Acoramidis, low-dose infigratinib and Encaleret continue to progress through clinical trials.

BridgeBio Pharma reported a decrease in operating expenses by 15.9% compared to Q2 2022, alongside positive data updates for its LGMD2i and KRAS programs. The company ended the quarter with $558.3 million in cash, providing financial runway into 2024.

BridgeBio Pharma reported positive proof-of-concept data in three key programs and five additional early-to-mid-stage pipeline programs. They entered an exclusive license agreement with Bristol Myers Squibb for BBP-398 and announced the sale of a Priority Review Voucher. The company ended the quarter with $688.6 million in cash, cash equivalents and marketable securities.

BridgeBio Pharma reported its Q1 2022 financial results, highlighting the sale of NULIBRY™ and an updated strategic collaboration with Helsinn Group. The company ended the quarter with $633.5 million in cash, cash equivalents, and marketable securities, providing financial runway into 2024.

BridgeBio Pharma reported its financial results for the fourth quarter ended December 31, 2021, revealing cash, cash equivalents, and marketable securities totaling $787.5 million. The company's operating costs and expenses for the quarter increased by $50.9 million to $178.5 million, driven by increased investment in research and development programs.

BridgeBio Pharma reported its Q3 2021 financial results, highlighting the topline results from Part A of the Phase 3 ATTRibute-CM trial expected by the end of 2021, progress in the RAS cancer portfolio, advancements in the gene therapy pipeline, and the repurchase of $148.4 million in common stock. The company ended the quarter with $599.6 million in cash, cash equivalents, and marketable securities.

BridgeBio Pharma reported its Q2 2021 financial results, with a key highlight being the FDA approval of TRUSELTIQ™ for cholangiocarcinoma. The company ended the quarter with $898.4 million in cash, cash equivalents, and marketable securities. Total revenues for the quarter were $54.0 million, and operating costs and expenses were $148.0 million.

BridgeBio reported first quarter results, highlighted by the FDA approval of NULIBRY, proof-of-concept data for encaleret in ADH1, a strategic collaboration with Helsinn Group for infigratinib, the completion of the Eidos Therapeutics acquisition, and nearly $750 million raised through convertible senior notes. The company ended the quarter with $1,001.3 million in cash, cash equivalents and marketable securities.

BridgeBio Pharma reported its Q4 and full year 2020 financial results, highlighting the completion of the Eidos Therapeutics acquisition and progress in clinical trials. The company ended the quarter with $607.1 million in cash, cash equivalents, and marketable securities.

BridgeBio reported $710.7 million in cash, cash equivalents and marketable securities as of September 30, 2020. The company had an operating expense of $128.1 million for the quarter. The company also announced a merger agreement with Eidos Therapeutics and the FDA accepted the NDA for Fosdenopterin under Priority Review.

BridgeBio Pharma reported its Q2 2020 financial results, highlighting the initiation of four clinical trials, progression of 11 ongoing trials, and submission of three INDs to the FDA. The company ended the quarter with $840.9 million in cash, cash equivalents, and marketable securities and expanded its global reach through a collaboration with LianBio.

BridgeBio Pharma reported its Q1 2020 financial results, ending the quarter with $928.4 million in cash, cash equivalents, and marketable securities. The company is managing the impact of the COVID-19 pandemic on its clinical trials and drug development programs and expects current cash to carry it through critical milestones into 2022.

BridgeBio Pharma reported its Q4 and full year 2019 financial results, showcasing pipeline expansion with the addition of five new drug development programs. The company ended the quarter with $577.1 million in cash, cash equivalents, and marketable securities.